Innate Pharma (IPHA) Depreciation & Amortization (CF) (2020 - 2025)

Innate Pharma (IPHA) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $1.6 million the latest figure, recorded in Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 30.59% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (down 52.32% YoY) and the FY2025 annual result came in at $1.6 million, down 30.59% from the prior year.
• Depreciation & Amortization (CF) slipped to $1.6 million in Q4 2025 per IPHA's latest filing, from $2.3 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for IPHA reached as high as $51.7 million in Q4 2022 and fell as low as $1.6 million in Q4 2025.
• A 5-year average of $13.3 million and a median of $5.2 million in 2021 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) plunged 91.91% — and 2022, when it jumped 887.92%.
• Year by year, Depreciation & Amortization (CF) stood at $5.2 million in 2021, then soared by 887.92% to $51.7 million in 2022, then plunged by 88.79% to $5.8 million in 2023, then plunged by 60.83% to $2.3 million in 2024, then sank by 30.59% to $1.6 million in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.6 million, $2.3 million, and $5.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.